Craig M Zaidman
Overview
Explore the profile of Craig M Zaidman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McMillan H, Baranello G, Farrar M, Zaidman C, Moreno T, Waele L, et al.
Neurology
. 2025 Jan;
104(2):e210268.
PMID: 39804575
Background And Objectives: Safety and efficacy of IV onasemnogene abeparvovec has been demonstrated for patients with spinal muscular atrophy (SMA) weighing <8.5 kg. SMART was the first clinical trial to...
2.
Potter R, Moeller I, Khan S, Haegel H, Hollenstein A, Steiner G, et al.
Sci Rep
. 2025 Jan;
15(1):4.
PMID: 39747998
Delandistrogene moxeparvovec is an rAAVrh74 vector-based gene transfer therapy that delivers a transgene encoding delandistrogene moxeparvovec micro-dystrophin, an engineered, functional form of dystrophin shown to stabilize or slow disease progression...
3.
OBrien M, Culican S, Shinawi M, Zaidman C
Neurology
. 2024 Nov;
103(11):e209969.
PMID: 39546739
Riboflavin transporter deficiency (RTD), previously referred to as Brown-Vialetto-Van Laere syndrome, is caused by pathogenic variants in the , , or genes, resulting in RTD types 1, 2, and 3,...
4.
Mendell J, Muntoni F, McDonald C, Mercuri E, Ciafaloni E, Komaki H, et al.
Nat Med
. 2024 Oct;
31(1):332-341.
PMID: 39385046
Duchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease caused by pathogenic variants in the DMD gene that result in the absence of functional dystrophin, beginning at birth and...
5.
Goedeker N, Rogers A, Fisher M, Arya K, Brandsema J, Farah H, et al.
Muscle Nerve
. 2024 Oct;
70(6):1247-1256.
PMID: 39370660
Introduction/aims: While prompt identification and treatment of infants with spinal muscular atrophy (SMA) can ameliorate outcomes, variability persists. This study assessed management and outcomes of early-treated infants with SMA. Methods:...
6.
Zaidman C, Crockett C, Wedge E, Tabatabai G, Goedeker N
Int J Neonatal Screen
. 2024 Aug;
10(3).
PMID: 39189230
In the United States (U.S.), newborn screening (NBS) for spinal muscular atrophy (SMA) is implemented by individual states. There is likely variation in the practice patterns of state NBS programs...
7.
Iannaccone S, Cai C, Rhem B, Batley K, Rajaram V, Greenberg B, et al.
J Neurol
. 2024 Jun;
271(8):5659-5664.
PMID: 38907024
No abstract available.
8.
Zaidman C, Goedeker N, Aqul A, Butterfield R, Connolly A, Crystal R, et al.
J Neuromuscul Dis
. 2024 Apr;
11(3):687-699.
PMID: 38607761
Background: Duchenne muscular dystrophy (DMD) is a rare, degenerative, recessive X-linked neuromuscular disease. Mutations in the gene encoding dystrophin lead to the absence of functional dystrophin protein. Individuals living with...
9.
Mercuri E, Vilchez J, Boespflug-Tanguy O, Zaidman C, Mah J, Goemans N, et al.
Lancet Neurol
. 2024 Mar;
23(4):393-403.
PMID: 38508835
Background: Duchenne muscular dystrophy, the most common childhood muscular dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have suggested that givinostat, a histone deacetylase inhibitor, might...
10.
Mendell J, Proud C, Zaidman C, Mason S, Darton E, Wang S, et al.
Pediatr Neurol
. 2024 Feb;
153:11-18.
PMID: 38306745
Background: Delandistrogene moxeparvovec is a gene transfer therapy approved in the United States, United Arab Emirates, and Qatar for the treatment of ambulatory patients aged four through five years with...